Jennifer Lo is CEO & President of BioJENC, a biotech company in the USA (State of Louisiana) with a focus on developing novel cancer diagnostics and therapeutics. Before completing her Ph.D. Program, she was Director of Special Programs for LUMCON (Louisiana Universities Marine Consortium) under the Board of Regents administering federal grants and contracts. When she was a graduate student at the Louisiana State University, she was mentored by Dr. Fu-Kuen Lin who later was inventor of Amgen's first medicine, Epogen, that became one of the most successful drugs of biotech history. Post graduation, she was Director of Research and Development at Anomeric, Inc., a biotech company also in Louisiana with a focus on development of new fungal diagnostic kits. At BioJENC, Dr. Lo had collaborations with Dr. Terrence Tumpey at the Influenza Division of the US Centers for Disease Control and Prevention on projects concerning avian, swine, and human influenza viruses. She also collaborated with Dr. Chyang Fang of the American Red Cross on a project concerning bacterial detection in platelet transfusion products using a rapid growth culture medium invented by Dr. Lo. After the company changed the research and development focus to developing anticancer therapy with the Granzyme B-like Peptides, she had collaborations with Dr. Alfred Lam at the Cancer Molecular Pathology of Griffith University in Australia and Professor Robert Hendricks in the Department of Ophthalmology of the University of Pittsburgh. Dr. Lo invented the Granzyme B-like peptides, useful to serve as a surrogate for Cytotoxic T Lymphocytes of the immune response, applicable for use in development of novel diagnostic tests and prevention/ treatment against cancer and infection (may even be applicable to inflammatory diseases/autoimmune diseases/Alzheimer's disease). She and Dr. Donald Luther have published three reports (2014, 2016) on peptide binding affinity with tumor cells, platelets, virally associated cells, and bacteria; and peptide cytotoxicity in tumor cells. She has just finished a successful in vivo peptide toxicity and efficacy study (in HSV-1 infected mice) supported by the US NIH, NIAID contract to the University of Alabama at Birmingham. An official at the US National Cancer Institute (NCI) suggested that the Granzyme B-like peptide may be applicable for use in immunopreventative/ chemopreventative intervention to help prevent premalignant tumors from progressing to malignant tumors (e.g. For use to effect prevention of cervical intraepithelial neoplasia (CIN) from malignancy progression in HPV- seropositive patients (may also include HIV+ patients). With the proof of concept provided by the NIH in vivo study, Dr. Lo is moving the peptide forward to developing a new form of liquid biopsy for use to help doctors assess the strength of the patient's immune response to disease progression including but not limited to cancer progression with and without a viral cause, and moving the peptide forward into clinical testing for efficacy against cancer with and without a viral cause.She is the co-inventor of 6 patents.